Cytodyn Inc (CYDY)

[moneycrew]

Leronlimab showed non-clinical effect for metastatic triple negative breast cancer:”Herein, leronlimab was shown to bind CCR5 in multiple breast cancer cell lines. Binding of leronlimab to CCR5 reduced ligand-induced Ca+?2 signaling, invasion of TNBC into Matrigel, and transwell migration. Leronlimab enhanced the BCa cell killing of the BCa chemotherapy reagent, doxorubicin. In xenografts conducted with Nu/Nu mice, leronlimab reduced lung metastasis of the TNBC cell line, MB-MDA-231, by >?98% at 6?weeks. Treatment with leronlimab reduced the metastatic tumor burden of established TNBC lung metastasis.”